<img height="1" width="1" style="display:none;" alt="" src="https://px.ads.linkedin.com/collect/?pid=2653956&amp;fmt=gif">
Image Overlay - DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial
Image Overlay - DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial

DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial

January 15, 2020

DURECT Corporation Announces Results From Phase 2a Clinical Psoriasis Trial

DURECT’s psoriasis treatment, DUR-928, did not demonstrate a significant benefit over a placebo in trials, though it was well tolerated in the 22 patients tested. Based on these results, the company will stop development on DUR-928 and will instead focus on their alcoholic hepatitis treatment, which achieved positive results in its phase 2a trial. While not all clinical trials are successful, Yourway provides solutions and services to move a therapy all the way through to commercialization. 

 Back to Index
Stay Connected

Want to stay informed about the latest news, updates, and opportunities at Yourway?

Join our newsletter mailing list to never miss an update!

Media

Upcoming Events

Clinical Trial Supply New England

April 14-15, 2026
Boston, MA

GCSG 2026 US Conference

April 27-29, 2026
San Diego, CA

Media

Articles

White-Glove by Design: The Yourway Standard in Clinical Logistics

Open chat
Come chat with us!
Hello! How can I help you?